Combined treatment with ruxolitinib and MK-2206 inhibits ERα activity by inhibiting MAPK signaling in BT474 breast cancer cells

Abstract

Triple-positive breast cancer (TPBC) is a type of breast cancer that overexpresses estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2). Dysregulation of ER signaling has been implicated in the pathogenesis of breast cancer. ERα activation triggers the production of second messengers, including cAMP, leading to the activation of signals such as PI3K/AKT or Ras/MAPK. Ruxolitinib is a specific inhibitor of JAK1/JAK2. MK-2206 is an allosteric inhibitor of the Akt. The limitations of the use of ruxolitinib and MK-2206 as single agents necessitate the development of combination therapies with other drugs. This study is the first to investigate the effects of combining ruxolitinib with MK-2206 on MAPK and PI3K/AKT signaling in BT474 breast cancer cells. In addition, this work aimed to increase the anticancer effects of cotreatment with MK-2206 and ruxolitinib. Ruxolitinib, MK-2206, and their combination reduced cell viability in a dose- and time-dependent manner, as determined by MTT assays after 48 h of treatment. Colony formation and wound healing assays demonstrated that MK-2206 exhibited a synergistic anti-proliferative effect. The effects of ruxolitinib, MK-2206, and their combination on PI3K/AKT and MAPK signaling were assessed via western blotting. Ruxolitinib and MK-2206 combined treatment inhibit cell death in BT474 cells by downregulating ERα, Src-1, ERK1/2, SAPK/JNK, and c-Jun. Our results revealed the relationships among the ERα, PI3K/AKT, and MAPK signaling pathways in ER+ breast cancer cells. Understanding the interactions among ERα, PI3K-AKT-mTOR, and MAPK could lead to novel combination therapies.

Keywords

BT474 ruxolitinib MK-2206 PI3K/AKT MAPK estrogen receptor

Get full access to this article

View all access options for this article.

References

Lopez-Mendez

Ventura-Gallegos

Camacho-Arroyo

, et al. The inhibitory effect of trastuzumab on BT474 triple-positive breast cancer cell viability is reversed by the combination of progesterone and estradiol. Oncol Lett 2024; 27: 19.

Liang

Zhang

Song

, et al. Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets. Semin Cancer Biol 2020; 60: 14–27.

Clusan

Ferrière

Flouriot

, et al. A basic review on estrogen receptor signaling pathways in breast cancer. Int J Mol Sci 2023; 24: 6834.

Harbeck

Penault-Llorca

Cortes

, et al. Breast cancer. Nat Rev Dis Primers 2019; 5: 66.

Alves

Ditzel

HJ.

Drugging the PI3K/AKT/mTOR pathway in ER+ breast cancer. Int J Mol Sci 2023; 24: 4522.

Stemke-Hale

Gonzalez-Angulo

Lluch

, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008; 68: 6084–6091.

Richter

Fischer

Holz

, et al. Combined application of pan-akt inhibitor MK-2206 and bcl-2 antagonist venetoclax in b-cell precursor acute lymphoblastic leukemia. Int J Mol Sci 2021; 22: 2771.

Razandi

Alton

Pedram

, et al. Identification of a structural determinant necessary for the localization and function of estrogen receptor α at the plasma membrane. Mol Cell Biol 2003; 23: 1633–1646.

Niederst

Engelman

JA.

Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci Signal 2013; 6: re6.

10.

Toulany

Minjgee

Saki

, et al. ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition. Cancer Biol Ther 2014; 15: 317–328.

11.

Eroglu

Celik

Kaya

, et al. Investigation of methylation profiles of TP53, Caspase 9, Caspase 8, Caspase 3 genes treated with DNA methyl transferase inhibitor (DNMTi) Zebularine (ZEB) and caffeic acid phenethyl ester (CAPE) on MCF-7 and MDA-MB-231 breast cancer cell lines. J Cancer Ther 2019; 10: 69–85.

12.

Celik

Eroglu

Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line. Mol Biol Rep 2023; 50: 319–329.

13.

Lim

Jeon

Gwak

, et al. Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor-positive, human epidermal growth factor receptor 2-positive breast cancer cells. Mol Med Rep 2018; 17: 5581–5588.

14.

Civallero

Cosenza

Pozzi

, et al. Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases. Oncotarget 2017; 8: 103797–103814.

15.

Tao

Yin

Shen

, et al. Akt inhibitor MK-2206 enhances the effect of cisplatin in gastric cancer cells. Biomed Rep 2016; 4: 365–368.

16.

BBY

Lui

VWY

Hui

CWC

, et al. Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines. Invest New Drugs 2013; 31: 567–575.

17.

Simioni

Neri

Tabellini

, et al. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia 2012; 26: 2336–2342.

18.

Jiao

Zhou

Yang

, et al. MK-2206 induces cell cycle arrest and apoptosis in HepG2 cells and sensitizes TRAIL-mediated cell death. Mol Cell Biochem 2013; 382: 217–224.

19.

Wilson

Kunnimalaiyaan

Gamblin

, et al. MK2206 inhibits hepatocellular carcinoma cellular proliferation via induction of apoptosis and cell cycle arrest. J Surg Res 2014; 191: 280–285.

20.

Celik

Eroglu

Ruxolitinib-loaded poly-ε-caprolactone (PCL) nanoparticles inhibit JAK2/STAT5 signaling in BT474 breast cancer cells by downregulating Bcl-2 and Mcl-1. Mol Biol Rep 2024; 51: 832.

21.

Mal

Magner

David

, et al. Estrogen receptor beta (ERβ): a ligand activated tumor suppressor. Front Oncol 2020; 10: 587386.

22.

Yang

Nie

, et al. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer 2019; 18: 26.

23.

Godone

RLN

Leitão

Araújo

, et al. Clinical and molecular aspects of breast cancer: targets and therapies. Biomed Pharmacother 2018; 106: 14–34.

24.

Mascarenhas

Hoffman

Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res 2012; 18: 3008–3014.

25.

Stover

Xiong

Myers

, et al. A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. Gynecol Oncol Rep 2022; 40: 100974.

26.

Kim

Lee

SC.

The inositide signaling pathway as a target for treating gastric cancer and colorectal cancer. Front Physiol 2016; 7: 168.

27.

Weng

Hsu

J-L

, et al. The combination of MK-2206 and WZB117 exerts a synergistic cytotoxic effect against breast cancer cells. Front Pharmacol 2019; 10: 1311.

28.

Sangai

Akcakanat

Chen

, et al. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res 2012; 18: 5816–5828.

29.

Schneider

Jeon

Suh

, et al. Effects of Ruxolitinib and Calcitriol combination treatment on various molecular subtypes of breast cancer. Int J Mol Sci 2022; 23: 2535.

30.

Savaee

Bakhshi

Yaghoubi

, et al. Evaluating the effects of separate and concomitant use of MK-2206 and salinomycin on prostate cancer cell line. Rep Biochem Mol Biol 2022; 11: 157–165.

31.

Tavallai

Booth

Roberts

, et al. Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS. Oncotarget 2016; 7: 17290–17300.

32.

Khan

Huang

Wen

, et al. AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia 2013; 27: 1882–1890.

33.

Sim

Song

Lee

SY.

Kv3 channels contribute to cancer cell migration via vimentin regulation. Biochem Biophys Res Commun 2021; 551: 140–147.

34.

Wada

Penninger

JM.

Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004; 23: 2838–2849.

35.

Avruch

Zhang

Kyriakis

JM.

Raf meets Ras: completing the framework of a signal transduction pathway. Trends Biochem Sci 1994; 19: 279–283.

36.

Zaballos

Santisteban

Key signaling pathways in thyroid cancer. J Endocrinol 2017; 235: R43–R61.

37.

Cao

Wang

Jiang

, et al. JAK1/2 inhibitor ruxolitinib promotes the expansion and suppressive action of polymorphonuclear myeloid-derived suppressor cells via the JAK/STAT and ROS-MAPK/NF-κB signalling pathways in acute graft-versus-host disease. Clin Transl Immunology 2023; 12: e1441.

38.

Brkic

Stivala

Santopolo

, et al. Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy. Leukemia 2021; 35: 2875–2884.

39.

Vagia

Mahalingam

Cristofanilli

The landscape of targeted therapies in TNBC. Cancers (Basel) 2020; 12: 916.

40.

Bader

Kang

Zhao

, et al. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005; 5: 921–929.

41.

Thorpe

Spangle

Ohlson

, et al. PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α. Proc Natl Acad Sci USA 2017; 114: 7095–7100.

42.

Blanco-Aparicio

Renner

Leal

JFM

, et al. PTEN, more than the AKT pathway. Carcinogenesis 2007; 28: 1379–1386.

43.

Karagianni

Piperi

Mpakou

, et al. Ruxolitinib with resminostat exert synergistic antitumor effects in cutaneous T-cell lymphoma. PLoS One 2021; 16: e0248298.

44.

Hirai

Sootome

Nakatsuru

, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010; 9: 1956–1967.

45.

Stottrup

Tsang

Chin

YR.

Upregulation of AKT3 inhibitor MK2206 in breast cancer. Mol Cancer Ther 2016; 15: 1964–1974.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

1.11 MB